Earnings Feed
Start Free
Alamar Biosciences, Inc.·4

Apr 20, 8:33 PM ET

Luo Yuling 4

4 · Alamar Biosciences, Inc. · Filed Apr 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Alamar Biosciences (ALMR) CEO Luo Yuling Converts Derivatives, Receives RSUs

What Happened

  • Luo Yuling, CEO of Alamar Biosciences (ALMR), converted several blocks of previously held convertible securities into common stock and received RSU awards. The filing shows multiple zero-dollar conversions and reclassifications of share classes on/around April 16–20, 2026, plus two RSU grants totaling 417,700 shares (341,191 on 4/16 and 76,509 on 4/20) issued at $0.00.
  • The conversion/reclassification entries include large blocks reported in the filing (examples): 1,864,065; 1,386,746; 1,224,152; 1,033,912; and 364,268 shares, among other smaller blocks. Most conversions and related “other acquisition/disposition” entries were recorded at $0 (non-cash), reflecting conversion of convertible/preferred instruments and internal reclassification rather than an open-market buy or sale.

Key Details

  • Transaction dates: primarily April 16, 2026 (RSU grant) and April 20, 2026 (conversions, reclassifications, RSU grant).
  • Prices: All conversions and RSU grants reported at $0.00 (non-cash). No cash purchases or open-market sales reported.
  • RSU totals: 341,191 RSUs granted 4/16/2026 and 76,509 RSUs granted 4/20/2026 = 417,700 RSUs awarded.
  • Notable converted blocks (as reported): 1,864,065; 1,386,746; 1,224,152; 1,033,912; 364,268 shares (plus several smaller blocks).
  • Footnotes: Conversions reflect automatic reclassification/conversion of Class A, Founders Preferred and Series A-1 Preferred into common stock prior to the IPO (see F1–F3). Several awards/options have time-based monthly vesting schedules (see F4, F5, F7–F11); some grants are fully vested per the filing (F6).
  • Filing timeliness: filing dated April 20, 2026 for transactions reported 4/16–4/20; no late-filing flag noted in the provided data.

Context

  • These entries are largely non-cash corporate actions (conversion/reclassification of convertible securities and issuance of RSUs) related to capital-structure changes around the IPO. They do not reflect an open-market purchase or sale that would indicate immediate bullish or bearish trading intent.
  • For retail investors: conversions and zero-dollar RSU grants are routine following IPO-related restructurings and reflect internal ownership reclassification or compensation, not a cash investment or sale by the CEO.

Insider Transaction Report

Form 4
Period: 2026-04-16
Alamar Biosciences, Inc.ALMR
Luo Yuling
DirectorChief Executive Officer
Transactions
  • Conversion

    Class B Common Stock

    [F1]
    2026-04-20+1,386,746→ 1,499,797 total
  • Conversion

    Class B Common Stock

    [F2]
    2026-04-20+364,268→ 1,864,065 total
  • Other

    Class B Common Stock

    [F3]
    2026-04-20−1,864,065→ 0 total
  • Other

    Common Stock

    [F3]
    2026-04-20+1,864,065→ 1,864,065 total
  • Award

    Common Stock

    [F4]
    2026-04-20+76,509→ 1,940,574 total
  • Conversion

    Class B Common Stock

    [F1]
    2026-04-20+1,224,152→ 1,224,152 total(indirect: By Spouse)
  • Other

    Class B Common Stock

    [F3]
    2026-04-20−1,224,152→ 0 total(indirect: By Spouse)
  • Other

    Common Stock

    [F3]
    2026-04-20+1,224,152→ 1,224,152 total(indirect: By Spouse)
  • Award

    Stock Option (Right to Buy)

    [F5]
    2026-04-16+341,191→ 341,191 total
    Exercise: $17.00Exp: 2036-04-15→ Common Stock (341,191 underlying)
  • Conversion

    Class A Common Stock

    [F1]
    2026-04-20−1,020,742→ 0 total
    → Class B Common Stock (1,020,742 underlying)
  • Conversion

    Founders Preferred Stock

    [F1]
    2026-04-20−366,004→ 0 total
    → Class B Common Stock (366,004 underlying)
  • Conversion

    Series A-1 Preferred Stock

    [F2]
    2026-04-20−880,802→ 0 total
    → Class B Common Stock (364,268 underlying)
  • Conversion

    Class A Common Stock

    [F1]
    2026-04-20−1,224,152→ 0 total(indirect: By Spouse)
    → Class B Common Stock (1,224,152 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F6]
    2026-04-20−266,311→ 0 total
    Exercise: $2.51Exp: 2027-02-15→ Class B Common Stock (266,311 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F6]
    2026-04-20+266,311→ 266,311 total
    Exercise: $2.51Exp: 2027-02-15→ Common Stock (266,311 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F6]
    2026-04-20−25,310→ 0 total
    Exercise: $2.51Exp: 2027-02-15→ Class B Common Stock (25,310 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F6]
    2026-04-20+25,310→ 25,310 total
    Exercise: $2.51Exp: 2027-02-15→ Common Stock (25,310 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F7]
    2026-04-20−23,986→ 0 total
    Exercise: $1.53Exp: 2033-01-17→ Class B Common Stock (23,986 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F7]
    2026-04-20+23,986→ 23,986 total
    Exercise: $1.53Exp: 2033-01-17→ Common Stock (23,986 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F6]
    2026-04-20−20,023→ 0 total
    Exercise: $1.53Exp: 2033-04-24→ Class B Common Stock (20,023 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F6]
    2026-04-20+20,023→ 20,023 total
    Exercise: $1.53Exp: 2033-04-24→ Common Stock (20,023 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F8]
    2026-04-20−27,700→ 0 total
    Exercise: $3.34Exp: 2034-04-16→ Class B Common Stock (27,700 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F8]
    2026-04-20+27,700→ 27,700 total
    Exercise: $3.34Exp: 2034-04-16→ Common Stock (27,700 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F9]
    2026-04-20−1,033,912→ 0 total
    Exercise: $3.34Exp: 2035-01-15→ Class B Common Stock (1,033,912 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F9]
    2026-04-20+1,033,912→ 1,033,912 total
    Exercise: $3.34Exp: 2035-01-15→ Common Stock (1,033,912 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F10]
    2026-04-20−37,086→ 0 total
    Exercise: $3.34Exp: 2035-01-15→ Class B Common Stock (37,086 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F10]
    2026-04-20+37,086→ 37,086 total
    Exercise: $3.34Exp: 2035-01-15→ Common Stock (37,086 underlying)
  • Other

    Stock Option (Right to Buy)

    [F3][F11]
    2026-04-20−42,334→ 0 total
    Exercise: $7.60Exp: 2036-01-14→ Class B Common Stock (42,334 underlying)
  • Other

    Stock Option ((Right to Buy)

    [F3][F11]
    2026-04-20+42,334→ 42,334 total
    Exercise: $7.60Exp: 2036-01-14→ Common Stock (42,334 underlying)
Footnotes (11)
  • [F1]The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
  • [F10]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
  • [F11]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
  • [F2]The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
  • [F3]Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
  • [F4]Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
  • [F5]Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
  • [F6]Fully vested.
  • [F7]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date.
  • [F8]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.
  • [F9]The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
Signature
/s/ Timothy White, Attorney-in-Fact|2026-04-20

Documents

1 file
  • 4
    form4-04212026_120453.xmlPrimary